NEW YORK (GenomeWeb News) – Proteome Sciences will supply its tandem mass tag — or TMT — technology to German drug discovery company Cellzome, Proteome Sciences announced today.
Cellzome was an early beta test site for Proteome Sciences’ TMTsixplex, which allows up to six samples to be labeled, mixed, and subsequently identified. Now, Cellzome plans to apply the TMTsixplex technology to its own proteomics platform approach for analyzing protein-drug and protein-protein interactions.
This chemical proteomics platform uses isobaric mass tags — different forms of a molecule with the same mass — to specifically label various peptides or proteins. For instance, Cellzome is aiming to treat inflammatory diseases such as asthma and allergic rhinitis by developing drugs that target kinases. Its so-called Kinobeads are used for quantitatively measuring interactions between various compounds and kinases.
“We have found the TMTsixplex a useful tool for our quantitative proteomics studies,” Cellzome Director of Analytical Sciences Marcus Bantscheff said in a statement. “With this isobaric mass tagging technology we can now do six point measurements in a single mass spectrometric experiment.”
Financial terms of the agreement were not disclosed.